Myriad Genetics announces breakthrough prenatal cfDNA screening study, awarded by SMFM, enabling results as early as eight weeks gestation.
Quiver AI Summary
Myriad Genetics, Inc. announced it will present significant research on early prenatal testing at the Society for Maternal-Fetal Medicine Conference. The study, awarded the Dru Carlson Memorial Award, demonstrates that its Prequel® Prenatal Screen utilizing AMPLIFY™ technology can provide accurate prenatal cell-free DNA (cfDNA) screening results as early as eight weeks of gestation, advancing the typical screening timeline of nine to ten weeks. This technology effectively increases the fetal fraction, yielding an average of 12.5% fetal cfDNA with a low no-call rate, enabling earlier risk assessment for chromosomal disorders. This advancement allows patients to make informed decisions regarding their care at a crucial early stage in pregnancy. The findings will be shared during a plenary session at the conference, emphasizing the importance of this technological breakthrough in prenatal genetic screening.
Potential Positives
- Myriad Genetics is unveiling groundbreaking research at the Society for Maternal-Fetal Medicine Conference, highlighting their leadership in genetic testing and precision medicine.
- The study on Prequel® Prenatal Screen with AMPLIFY™ technology received the “Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics,” indicating recognition for its scientific contribution.
- The ability to provide reliable prenatal screening results as early as eight weeks of gestation represents a significant advancement, improving patient care and decision-making timelines.
- This innovative testing method increases fetal fraction and reduces the no-call rate, enhancing the accuracy of genetic insights for expectant parents.
Potential Negatives
- The mention of "forward-looking statements" indicates potential uncertainty regarding the company’s future performance and market acceptance of its new technology, which may raise concerns among investors.
- The potential for "known and unknown risks and uncertainties" that could adversely impact the anticipated outcomes of the Prequel with AMPLIFY test may result in cautious reception from stakeholders.
- The predominance of technical jargon and complex scientific explanations may alienate non-specialist audiences, reducing the press release's overall accessibility and comprehension.
FAQ
What is the significance of Myriad Genetics' new research?
Myriad Genetics' research allows prenatal cell-free DNA screening as early as eight weeks gestation, a significant advancement in prenatal genetic testing.
What technology is used in the Prequel Prenatal Screen?
The Prequel Prenatal Screen utilizes AMPLIFY™ technology to increase fetal fraction, improving the reliability of results from eight weeks gestation.
What chromosomal conditions can the Prequel test assess?
The Prequel test can assess risks for conditions like Down syndrome, Edwards syndrome, Patau syndrome, and sex chromosome abnormalities.
When and where will the study results be presented?
The study results will be presented on January 30, 2025, at the Society for Maternal-Fetal Medicine Conference, Aurora Ballroom, 8:30 a.m. MT.
Who is presenting the research at the conference?
Dr. Lorraine Dugoff, Professor and Chief of Reproductive Genetics at the University of Pennsylvania, will present the research findings.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYGN Insider Trading Activity
$MYGN insiders have traded $MYGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:
- COLLEEN F REITAN sold 46,012 shares for an estimated $1,285,851
- PAUL J DIAZ (President and CEO) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $744,750.
- MARGARET ANCONA (SVP, Chief of Staff) sold 11,538 shares for an estimated $320,987
- HEINRICH DREISMANN sold 10,000 shares for an estimated $270,520
- RASHMI KUMAR sold 7,500 shares for an estimated $210,075
- DALE MUZZEY (Chief Scientific Officer) sold 2,100 shares for an estimated $54,961
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MYGN Hedge Fund Activity
We have seen 124 institutional investors add shares of $MYGN stock to their portfolio, and 106 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 2,486,902 shares (-66.3%) from their portfolio in Q3 2024, for an estimated $68,116,245
- CITADEL ADVISORS LLC removed 1,695,989 shares (-96.1%) from their portfolio in Q3 2024, for an estimated $46,453,138
- CAMBER CAPITAL MANAGEMENT LP removed 1,550,000 shares (-28.2%) from their portfolio in Q3 2024, for an estimated $42,454,500
- WELLINGTON MANAGEMENT GROUP LLP removed 1,545,842 shares (-18.7%) from their portfolio in Q3 2024, for an estimated $42,340,612
- LOOMIS SAYLES & CO L P added 1,326,497 shares (+153.7%) to their portfolio in Q3 2024, for an estimated $36,332,752
- MILLENNIUM MANAGEMENT LLC added 777,499 shares (+17.7%) to their portfolio in Q3 2024, for an estimated $21,295,697
- MORGAN STANLEY removed 491,650 shares (-35.8%) from their portfolio in Q3 2024, for an estimated $13,466,293
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company’s “Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation” study was awarded SMFM’s “Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics.”
The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered beginning at nine to 10 weeks’ gestation. At earlier gestational ages, the proportion of placental cfDNA, referred to as the fetal fraction (FF), is often too low to allow for confident analysis. Prequel with AMPLIFY can overcome this limitation by increasing the FF. This study found that by using Prequel with AMPLIFY, the average FF was 12.5%, with a no-call rate of less than 0.5% between eight and 10 weeks of gestation.
“Being able to assess the risks for chromosomal disorders at eight weeks of pregnancy is a significant step forward in prenatal genetic screening,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “We are improving the timeline for patients to understand their risk assessment of chromosomal abnormalities, allowing pregnant patients to pursue earlier diagnostic testing, such as chorionic villus sampling at 10 weeks’ gestation, when recommended by their clinicians, instead of the typical 15 weeks for amniocentesis. Earlier, reliable results empower clinicians and their patients to make the most informed, timely decisions for their care.”
The data will be shared during an opening oral plenary session at 8:30 a.m. (MT) on Thursday, Jan. 30, 2025, in the Aurora Ballroom, Lobby Level. Lorraine Dugoff, MD, Professor, Chief of Reproductive Genetics, University of Pennsylvania, will present the study results.
About the Study
The objective of this multi-site study was to determine how early in gestation the Prequel with AMPLIFY test can deliver high-quality results. The enrolled subjects provided two samples for analysis: the first between six to nine weeks’ gestation and the second at ≥10 weeks’ gestation, where Prequel was already validated. Clinical results and FF levels were compared between each patient’s two samples, revealing that Prequel with AMPLIFY at eight weeks gestation has sufficiently high FF levels to return reliable results consistent with typical cfDNA screening at 10 weeks or later.
Additional Myriad Presentations as SMFM
Detecting maternal mosaicism in fetal sex chromosome aneuploidy screening
Poster session 1001
Date/Location: Friday, Jan. 31, 2025, 4:00 pm (MT)
Presenter: Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics
Summary: Sex chromosome anomalies (SCA) are a common class of fetal aneuploidy, but cfDNA screening assays typically have relatively low positive predictive value (PPV) for SCA calls. False positives are caused by factors including statistical error, confined placental mosaicism, and maternal mosaicism. To compare the impact of these factors and improve SCA screening PPV, Myriad Genetics developed a new “depth trajectory” method within its upcoming FirstGene™ product that identifies mosaic maternal aneuploidy by analyzing covariation in read depth and DNA fragment size.
About Prequel Prenatal Screen
Myriad’s Prequel
®
Prenatal Screen with AMPLIFY™ technology is the first and only prenatal cfDNA screen available at eight-weeks' gestational age. AMPLIFY technology has been shown to increase fetal fraction 2.3-fold on average, allowing the test to provide pregnant patients with genetic insights into fetal development and the health of the pregnancy as early as eight weeks’ gestation. Prequel with AMPLIFY can assess if a pregnancy is at an increased risk for several chromosomal conditions like Down, Edwards, or Patau syndrome, sex chromosome abnormalities, expanded aneuploidies, and select microdeletions, including 22q11.2.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit
www.myriad.com
.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the company’s belief that being able to assess the risks for chromosomal disorders at eight weeks of pregnancy is a significant step forward in prenatal genetic screening, through its Prequel with AMPLIFY test, the company is improving the timeline for patients to understand their risk assessment of chromosomal abnormalities, allowing pregnant patients to pursue earlier diagnostic testing, such as chorionic villus sampling at 10 weeks’ gestion, when recommended by their clinicians, instead of the typical 15 weeks for amniocentesis, and how earlier, reliable results empower clinicians and their patients to make the most informed, timely decisions for their care. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
[email protected]
Media Contact
Glenn Farrell
(385) 318-3718
[email protected]